蒙特利尔认知评估对新诊断高级别胶质瘤患者认知障碍筛查的敏感性
本研究评估蒙特利尔认知评估(MoCA)在新诊断高级别胶质瘤患者术后放化疗前筛查认知障碍的敏感性。156例患者接受MoCA和神经心理成套测验,以GRECOGVASC研究的1003名对照数据为参照,通过ROC曲线分析发现MoCA原始和调整分数的曲线下面积分别为0.759和0.788,敏感性仅中等,结论认为MoCA不适合作为该人群的认知障碍筛查工具。
要点
- MoCA筛查新诊断高级别胶质瘤患者认知障碍的敏感性仅中等。
- 原始分≤25时敏感性0.526、特异性0.832,阳性预测值0.2、阴性预测值0.96。
- 调整分≤-0.603时敏感性0.716、特异性0.768,阳性预测值0.24、阴性预测值0.96。
核心结论
- MoCA敏感性中等,不适合用于新诊断高级别胶质瘤患者的认知障碍筛查。
研究设计与样本
- 研究纳入156例新诊断高级别胶质瘤患者,于术后、放化疗前评估认知。
- 采用MoCA和神经心理成套测验评估认知,并参照GRECOGVASC研究1003名对照数据进行分析。
主要发现
- MoCA原始分和调整分的ROC曲线下面积分别为0.759(95% CI 0.703-0.815)和0.788(95% CI 0.734-0.842)。
- 原始分≤25时敏感性0.526、特异性0.832、阳性预测值0.2、阴性预测值0.96。
- 调整分≤-0.603时敏感性0.716、特异性0.768、阳性预测值0.24、阴性预测值0.96。
关键数值与推荐
- MoCA原始分≤25为最佳判别阈值,敏感性0.526、特异性0.832。
- MoCA调整分≤-0.603为最佳判别阈值,敏感性0.716、特异性0.768。
临床怎么用
- 不推荐单独使用MoCA筛查新诊断高级别胶质瘤患者的认知障碍。
- 如需认知评估,应结合神经心理成套测验等更全面的方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cognitive impairment is frequent in patients with high-grade glioma and requires cognitive follow-up. Cognitive screening tools such as the Montreal Cognitive Assessment (MoCA) have been used to assess cognition in these patients. Here we assessed the sensitivity of the MoCA in screening for cognitive impairment in a cohort of 156 patients with newly-diagnosed high-grade glioma, after surgery and before radiochemotherapy. METHODS: We assessed cognitive performance with the MoCA and a neuropsychological battery. Cognitive scores were analyzed in terms of a previously validated framework designed to control false positives and data for 1003 control participants from the GRECOGVASC study. After comparison of performance on the tests, we used stepwise logistic regression to produce a cognitive summary score from the neuropsychological battery. Then we analyzed sensitivity and specificity of the MoCA with receiver operator characteristic (ROC) curve analysis. RESULTS: Both raw and adjusted MoCA scores showed only moderate sensitivity. The area under the ROC curve was 0.759 (95% CI 0.703-0.815) for the raw score and 0.788 (95% CI 0.734-0.842) for the adjusted score. Optimal discrimination was obtained with a raw score ≤ 25 (sensitivity: 0.526; specificity: 0.832; positive predictive value: 0.2; negative predictive value: 0.96) and an adjusted score - 0.603 (sensitivity: 0.716; specificity: 0.768; positive predictive value: 0.24; negative predictive value: 0.96). CONCLUSION: The moderate sensitivity of MoCA indicates that it is not a suitable screening tool for detecting cognitive impairment in patients with newly-diagnosed high-grade glioma.
引用
- Ribeiro M, Durand T, Roussel M, et al. Sensitivity of the Montreal Cognitive Assessment in screening for cognitive impairment in patients with newly diagnosed high-grade glioma. J Neurooncol. 2020. PMID: 32415644. doi:10.1007/s11060-020-03524-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。